2021

Parker, A. M. et al. (2021) Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. Lancet Respiratory Medicine, 9(11), pp. 1328-1341. (doi: 10.1016/S2213-2600(21)00385-4) (PMID:34678213) (PMCID:PMC8525917)

2013

McIlwaine, L., Parker, A., Sandilands, G., Gallipoli, P. and Leach, M. (2013) Neutrophil-specific granule deficiency. British Journal of Haematology, 160(6), p. 735. (doi: 10.1111/bjh.12207)

2010

Chakraverty, R. et al. (2010) Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood, 116(16), pp. 3080-3088. (doi: 10.1182/blood-2010-05-286856)

Parker, A., Bowles, K., Bradley, J.A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A. and Newstead, C. (2010) Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. British Journal of Haematology, 149(5), pp. 675-692. (doi: 10.1111/j.1365-2141.2010.08161.x)

2009

Thomson, K.J. et al. (2009) Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 27(3), pp. 426-432. (doi: 10.1200/JCO.2008.17.3328)

2008

Kubo, N., Akita, N., Shimizu, A., Kitahara, H.., Parker, A.L., Parker, A. and Miyagawa, S. (2008) Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection. Journal of Drug Targeting, 16(5), pp. 396-404. (doi: 10.1080/10611860802088796)

Parker, A., Parker, A., Mcvey, J., Waddington, S., Buckley, S., Francischetti, I., Monteiro, R., Nicklin, S. and Baker, A. (2008) An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy, 19(4), p. 34.

Waddington, S. et al. (2008) A critical role for the adenovirus serotype 5 hexon in liver gene transfer. Human Gene Therapy, 19(4), p. 40.

2007

Maclean, P., Parker, A., McQuaker, I., Clark, A., Farrell, E. and Douglas, K. (2007) Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplantation, 40(7), pp. 665-669. (doi: 10.1038/sj.bmt.1705789)

Peggs, K. et al. (2007) Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology, 139(1), pp. 70-80.

2005

Cummins, M. et al. (2005) Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplantation, 36(12), pp. 1065-1069. (doi: 10.1038/sj.bmt.1705180)

Allan, E., Jordanides, N., McLintock, L., Copland, M., Devaney, M., Stewart, K., Parker, A., Johnson, P., Holyoake, T. and Jones, B. (2005) Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. British Journal of Haematology, 128(4), pp. 578-579. (doi: 10.1111/j.1365-2141.2004.05333.x)

Peggs, K., Hunter, A., Chopra, R., Parker, A., Mahendra, P., Milligan, D., Craddock, C., Pettengell, R., Dogan, A. and Thomson, K. (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, 365(9475), p. 1934.

Tauro, S. et al. (2005) Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology, 23(36), pp. 9387-9393.

2004

Osborne, W., Holyoake, T., McQuaker, I. and Parker, A. (2004) Fatal peripheral neuropathy following FLA chemotherapy. Clinical and Laboratory Haematology, 26(4), pp. 295-296. (doi: 10.1111/j.1365-2257.2004.00613.x)

Ho, G.-T., Parker, A., MacKenzie, J. F., Morris, A. J. and Stanley, A. J. (2004) Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy. European Journal of Gastroenterology and Hepatology, 16(2), pp. 157-162. (doi: 10.1097/00042737-200402000-00006) (PMID:15075988)

McLintock, L., Jordanides, N., Allan, E., Copland, M., Stewart, K., Parker, A., Devaney, M., Holyoake, T. and Jones, B. (2004) The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. British Journal of Haematology, 124(3), pp. 403-404. (doi: 10.1046/j.1365-2141.2003.04794.x)

Marks, D., Parker, A. and Robinson, S. (2004) Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know.[comment]. Blood, 104(1), pp. 295-296.

Morris, E. et al. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104(13), pp. 3865-3871.

2002

Branson, K. et al. (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. Journal of Clinical Oncology, 20(19), pp. 4022-4031.

Chakraverty, R. et al. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.[see comment]. Blood, 99(3), pp. 1071-1078.

Clark, A., Douglas, K., Mitchell, L., McQuaker, I., Parker, A., Tansey, P., Franklin, I. and Cook, G. (2002) Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.[erratum appears in Br J Haematol 2002 Sep;118(4):1201]. British Journal of Haematology, 117(3), pp. 605-612.

Marks, D. et al. (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 100(9), pp. 3108-3114.

Perez-Simon, J. et al. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100(9), pp. 3121-3127.

Wilson, E., Jobanputra, S., Jackson, R., Parker, A. and McQuaker, I. (2002) Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. British Journal of Haematology, 119(1), pp. 128-130.

2001

Ljungman, P. et al. (2001) Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 28(5), pp. 479-484.

Robertson, J., Testa, N., Russell, N., Jackson, G., Parker, A., Milligan, D., Stainer, C., Chakrabarti, S., Dougal, M. and Chopra, R. (2001) Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplantation, 27(12), pp. 1283-1286.

Articles

Parker, A. M. et al. (2021) Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. Lancet Respiratory Medicine, 9(11), pp. 1328-1341. (doi: 10.1016/S2213-2600(21)00385-4) (PMID:34678213) (PMCID:PMC8525917)

McIlwaine, L., Parker, A., Sandilands, G., Gallipoli, P. and Leach, M. (2013) Neutrophil-specific granule deficiency. British Journal of Haematology, 160(6), p. 735. (doi: 10.1111/bjh.12207)

Chakraverty, R. et al. (2010) Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood, 116(16), pp. 3080-3088. (doi: 10.1182/blood-2010-05-286856)

Parker, A., Bowles, K., Bradley, J.A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A. and Newstead, C. (2010) Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. British Journal of Haematology, 149(5), pp. 675-692. (doi: 10.1111/j.1365-2141.2010.08161.x)

Thomson, K.J. et al. (2009) Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 27(3), pp. 426-432. (doi: 10.1200/JCO.2008.17.3328)

Kubo, N., Akita, N., Shimizu, A., Kitahara, H.., Parker, A.L., Parker, A. and Miyagawa, S. (2008) Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection. Journal of Drug Targeting, 16(5), pp. 396-404. (doi: 10.1080/10611860802088796)

Parker, A., Parker, A., Mcvey, J., Waddington, S., Buckley, S., Francischetti, I., Monteiro, R., Nicklin, S. and Baker, A. (2008) An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy, 19(4), p. 34.

Waddington, S. et al. (2008) A critical role for the adenovirus serotype 5 hexon in liver gene transfer. Human Gene Therapy, 19(4), p. 40.

Maclean, P., Parker, A., McQuaker, I., Clark, A., Farrell, E. and Douglas, K. (2007) Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplantation, 40(7), pp. 665-669. (doi: 10.1038/sj.bmt.1705789)

Peggs, K. et al. (2007) Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology, 139(1), pp. 70-80.

Cummins, M. et al. (2005) Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplantation, 36(12), pp. 1065-1069. (doi: 10.1038/sj.bmt.1705180)

Allan, E., Jordanides, N., McLintock, L., Copland, M., Devaney, M., Stewart, K., Parker, A., Johnson, P., Holyoake, T. and Jones, B. (2005) Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. British Journal of Haematology, 128(4), pp. 578-579. (doi: 10.1111/j.1365-2141.2004.05333.x)

Peggs, K., Hunter, A., Chopra, R., Parker, A., Mahendra, P., Milligan, D., Craddock, C., Pettengell, R., Dogan, A. and Thomson, K. (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, 365(9475), p. 1934.

Tauro, S. et al. (2005) Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology, 23(36), pp. 9387-9393.

Osborne, W., Holyoake, T., McQuaker, I. and Parker, A. (2004) Fatal peripheral neuropathy following FLA chemotherapy. Clinical and Laboratory Haematology, 26(4), pp. 295-296. (doi: 10.1111/j.1365-2257.2004.00613.x)

Ho, G.-T., Parker, A., MacKenzie, J. F., Morris, A. J. and Stanley, A. J. (2004) Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy. European Journal of Gastroenterology and Hepatology, 16(2), pp. 157-162. (doi: 10.1097/00042737-200402000-00006) (PMID:15075988)

McLintock, L., Jordanides, N., Allan, E., Copland, M., Stewart, K., Parker, A., Devaney, M., Holyoake, T. and Jones, B. (2004) The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. British Journal of Haematology, 124(3), pp. 403-404. (doi: 10.1046/j.1365-2141.2003.04794.x)

Marks, D., Parker, A. and Robinson, S. (2004) Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know.[comment]. Blood, 104(1), pp. 295-296.

Morris, E. et al. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104(13), pp. 3865-3871.

Branson, K. et al. (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. Journal of Clinical Oncology, 20(19), pp. 4022-4031.

Chakraverty, R. et al. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.[see comment]. Blood, 99(3), pp. 1071-1078.

Clark, A., Douglas, K., Mitchell, L., McQuaker, I., Parker, A., Tansey, P., Franklin, I. and Cook, G. (2002) Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.[erratum appears in Br J Haematol 2002 Sep;118(4):1201]. British Journal of Haematology, 117(3), pp. 605-612.

Marks, D. et al. (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 100(9), pp. 3108-3114.

Perez-Simon, J. et al. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100(9), pp. 3121-3127.

Wilson, E., Jobanputra, S., Jackson, R., Parker, A. and McQuaker, I. (2002) Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. British Journal of Haematology, 119(1), pp. 128-130.

Ljungman, P. et al. (2001) Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 28(5), pp. 479-484.

Robertson, J., Testa, N., Russell, N., Jackson, G., Parker, A., Milligan, D., Stainer, C., Chakrabarti, S., Dougal, M. and Chopra, R. (2001) Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplantation, 27(12), pp. 1283-1286.